Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilaria Stevani

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Tumori|May 7, 2002
Herceptin in elderly patientsClaudia Bighin, Ilaria Stevani, Marco Venturini
Tumori|June 25, 2010
Anti-androgen therapy suspension following prolonged clinical and biochemical response: outcomes in a series of elderly patients with advanced prostate cancerBruno Castagneto, Ilaria Stevani, Valentino Ferraris, et al.
Cancer|February 25, 2003
Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinomaMarco Venturini, Antonio Durando, Ornella Garrone, et al.
Clinical Genitourinary Cancer|October 5, 2023
TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective AnalysisChiara Pisano, Fabio Turco, Elena Arnaudo, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Tumori|May 7, 2002
Herceptin in elderly patientsClaudia Bighin, Ilaria Stevani, Marco Venturini
Tumori|June 25, 2010
Anti-androgen therapy suspension following prolonged clinical and biochemical response: outcomes in a series of elderly patients with advanced prostate cancerBruno Castagneto, Ilaria Stevani, Valentino Ferraris, et al.
Cancer|February 25, 2003
Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinomaMarco Venturini, Antonio Durando, Ornella Garrone, et al.
Clinical Genitourinary Cancer|October 5, 2023
TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective AnalysisChiara Pisano, Fabio Turco, Elena Arnaudo, et al.
Pageof 1